Table 1 Demographic and clinical characteristics of the study group

Age in years

Median (IQR)

38.5 (27)

36 (23)

= 0.456

Sex

Male

8/4

25/10

= 0.511

DM

Yes

1 (8.3%)

3 (8.6%)

= 0.743

HTN

Yes

0 (0%)

3 (8.6%)

= 0.404

Rural

Yes

7 (14.9%)

26 (55.3%)

0.03

Urban

Yes

5 (10.6%)

9 (19.1%)

SBP (mmHg)

Median (IQR)

120 (18)

110 (40)

= 0.110

DBP (mmHg)

Median (IQR)

80 (8)

70 (20)

= 0.029

Time from start of symptoms to sample collection/days

Median (IQR)

3 (12)

21 (20)

< 0.001

Time from start of symptoms to MRI/days

Median (IQR)

3 (12)

21 (20)

< 0.001

Presenting symptoms

Dyspnea

2 (16.7%)

17 (48.6%)

= 0.042

Angina

9 (75%)

5 (14.3%)

< 0.001

Pulmonary edema

0 (0%)

4 (11.4%)

= 0.294

Palpitation

2 (16.7%)

3 (8.5%)

= 0.583

Lower limb edema

0 (0%)

2 (5.7%)

= 0.550

Shock

0 (0%)

9 (25.7%)

= 0.166

ECG finding

Sinus tachycardia

10 (21.3%)

31 (66%)

= 0.428

ST segment raising

7 (14.9%)

6 (12.8%)

0.550

Atrial fibrillation

0 (0%)

2 (4.2%)

0.550

Ventricular tachycardia

2 (16.6%)

1 (2.8%)

= 0.798

Left bundle branch block

0 (0%)

6 (17.1%)

= 0.044

Right bundle branch block

0 (0%)

1 (2.8%)

= 0.852

EF% at presentation

Median (IQR)

55% (19)

40% (19)

= 0.007

≤ 40%

2 (16.7%)

13 (37.1%)

= 0.019

41–49%

2 (16.7%)

14 (40%)

≥ 50%

8 (66.6%)

8 (22.9%)

ESC position statement criteria

Median

5

4

0.1

Previous COVID by (history)

N (%)

1(2%)

9 (25.7%)

= 0.027

No previous COVID (by history)

11

26 (74.3%)

Troponin

Positive

11 (91.7%)

25 (71.4%)

= 0.150

Treatment given to the Patients

Digoxin/digitoxin

0 (0%)

1 (2.9%)

= 0.745

ACE inhibitor /angiotensin receptor blocker

5 (41.7%)

19 (54.3%)

= 0.450

Beta blockers

5 (41.7%)

18 (51.4%)

= 0.450

Diuretics

3 (25%)

23 (65.7%)

= 0.020

Spironolactone

3 (25%)

19 (54.3%)

= 0.079

Amiodarone

2 (16.7%)

3 (8.6%)

= 0.590

Steroids

4 (33.3%)

3 (8.6%)

= 0.038

NSAIDs

6 (50%)

5 (14.3%)

= 0.020

Colchicine

6 (50%)

5 (14.3%)

= 0.020